Penumbra, Inc. Stock

Equities

PEN

US70975L1070

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 16:00:02 2024-05-31 EDT 5-day change 1st Jan Change
189.5 USD +0.78% Intraday chart for Penumbra, Inc. -2.16% -24.68%
Sales 2024 * 1.24B 1.69B Sales 2025 * 1.44B 1.97B Capitalization 7.34B 10.01B
Net income 2024 * 107M 146M Net income 2025 * 150M 204M EV / Sales 2024 * 5.69 x
Net cash position 2024 * 289M 394M Net cash position 2025 * 398M 543M EV / Sales 2025 * 4.81 x
P/E ratio 2024 *
69.3 x
P/E ratio 2025 *
50.6 x
Employees 4,200
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.18%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.78%
1 week-2.16%
1 month-8.05%
3 months-19.94%
6 months-16.81%
Current year-24.68%
More quotes
1 week
185.12
Extreme 185.12
194.12
1 month
185.12
Extreme 185.12
220.41
Current year
185.12
Extreme 185.12
277.34
1 year
180.93
Extreme 180.93
348.67
3 years
114.87
Extreme 114.865
348.67
5 years
114.87
Extreme 114.865
348.67
10 years
35.32
Extreme 35.315
348.67
More quotes
Managers TitleAgeSince
Founder 62 04-06-20
Chief Executive Officer 62 04-06-20
Director of Finance/CFO 52 19-12-01
Members of the board TitleAgeSince
Director/Board Member 60 17-01-12
Director/Board Member 57 15-03-31
Chief Executive Officer 62 04-06-20
More insiders
Date Price Change Volume
24-05-31 189.5 +0.78% 435,845
24-05-30 188 -1.74% 512,191
24-05-29 191.3 -0.76% 211,101
24-05-28 192.8 -0.44% 230,879

Delayed Quote Nyse, May 31, 2024 at 04:00 pm

More quotes
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
189.5 USD
Average target price
270.8 USD
Spread / Average Target
+42.94%
Consensus